At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary...

Area of Science:

• Cardiovascular disease prevention
• Health economics
• Public health policy

Background:

• Current cholesterol-lowering drug treatment guidelines emphasize absolute coronary heart disease (CHD) risk.
• Assessing the entire risk factor profile is crucial before initiating treatment.
• This study focuses on primary prevention in Sweden, considering age and gender differences.

Purpose of the Study:

• To estimate the cost-effectiveness of initiating cholesterol-lowering drug treatment in primary prevention.
• To determine the coronary risk thresholds at which treatment becomes cost-effective for different age groups and genders in Sweden.
• To provide evidence for updating treatment guidelines based on economic evaluations.

Main Methods:

• Cost-effectiveness analysis using the incremental cost per quality-adjusted life-year (QALY) gained.
• A Markov model simulated CHD progression, with treatment assumed to reduce CHD risk by 31%.
• Societal perspective adopted, including direct/indirect costs and full future costs of decreased mortality, using willingness-to-pay thresholds of $40,000, $60,000, and $100,000 per QALY.

Main Results:

• Cost-effectiveness varied significantly by age and gender.
• At a $60,000/QALY threshold, treatment initiation was cost-effective for 35-year-old men at >2.4% 5-year CHD risk (women: >2.0%), 50-year-old men at >4.6% (women: >3.5%), and 70-year-old men at >10.4% (women: >9.1%).
• Lower risk thresholds were observed for women compared to men across all age groups.

Conclusions:

• The study provides age- and gender-specific coronary risk cut-offs for cost-effective cholesterol-lowering drug initiation.
• Results can inform the development of evidence-based treatment guidelines for primary prevention.
• Economic evaluations are essential for optimizing resource allocation in cardiovascular disease prevention strategies.